Follow the guidelines
XIFAXAN was given the highest possible recommendation by AASLD/EASL as an add-on therapy to lactulose for the reduction in risk of OHE recurrence2,*
XIFAXAN earned AASLD/EASL’s highest possible recommendation (GRADE I,A,1) as an add-on therapy to lactulose to reduce the risk of OHE recurrence after a patient has a recurrence while on lactulose alone.2,*
I,A,1 is the highest possible recommendation.2
Explore an important recommendation from the AASLD Guidelines
Watch Dr. Jesudian discuss some of the AASLD Guidelines for reducing the risk of OHE recurrence with XIFAXAN.
What can you do to help reduce your patients’ risk of OHE recurrence?
*Per the GRADE System for Evidence: Grade I=randomized, controlled trials; A=evidence is “high quality,” and further research is very unlikely to change our confidence in the estimated effect; and 1=recommendation is “strong,” with factors influencing strength of recommendation including the quality of evidence, presumed patient-important outcomes, and costs.2